Physician profile
Michael E Steuer
NPI 1659377257
$4,267.07
in general payments reported to CMS, 2019-2025
24 companies · $751 in 2025
The $751 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $188 · 2021: $604 · 2022: $493 · 2023: $624 · 2024: $1,078 · 2025: $751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,453.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,452.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,598.47 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Patient Trial Kit |
| Nevro Corp. | $573.14 | 2019-2024 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $531.18 | 2022-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $274.45 | 2019-2025 | Xtampza, Belbuca |
| Abbvie INC. | $200.26 | 2021-2022 | |
| Daiichi Sankyo INC. | $190.87 | 2019 | |
| Scilex Pharmaceuticals INC. | $152.16 | 2019-2025 | Ztlido |
| Medtronic USA, INC. | $133.21 | 2020 | |
| Medtronic, INC. | $89.44 | 2022-2024 | Emprint |
| Medline Industries LP | $87.64 | 2024 | |
| Si-Bone, INC. | $83.07 | 2024 | |
| Shionogi INC | $45.41 | 2019 | |
| Grt US Holding, INC. | $40.70 | 2021 | |
| Protega Pharmaceutials INC | $36.77 | 2024 | Roxybond |
| Nalu Medical, INC. | $35.55 | 2022-2023 | Nalu Neurostimulation System |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $28.77 | 2025 | Rs-4i Plus With Intersperse |
| Pacira Therapeutics, INC. | $27.59 | 2019 | |
| Arbor Pharmaceuticals, INC. | $27.09 | 2021 | |
| Averitas Pharma INC. | $23.59 | 2024 | Qutenza |
| Allergan, INC. | $22.37 | 2022 | |
| Abbott Laboratories | $18.31 | 2022 | |
| Redhill Biopharma INC. | $17.19 | 2021 | |
| Lundbeck LLC | $17.17 | 2024 | Vyepti |
| Lilly USA, LLC | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Steuer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.